Review: platelet alloantigens and antibodies and their clinical significance
By:
Paid access
|May 2020References
- Metcalfe P, Watkins NA, Ouwehand WH et al. Nomenclature of human platelet antigens. Vox Sang 203;85:240-5.
- Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987;70:1722-6.
- Metcalfe P, Waters AH. HPA-1 typing by PCR amplification with sequence-specific primers (PCR- SSP): a rapid and simple technique. Br J Haematol 1993;85:227-9.
- Jones DC, Bunce M, Fuggle SV, Young NT, Marshall SE. Human platelet alloantigens (HPAs): PCR-SSP genotyping of a UK population for 15 HPA alleles. Eur J Immunogenet 203;30:415-9.
- Woods Jr VL, Kurata Y, Montgomery RR, et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 1984a;64:156-60.
- George JN, Raskob GE. Idiopathic thrombocytopenic purpura: a concise summar y of the pathophysiology and diagnosis in children and adults. Semin Hematol 1998;35:5-8.
- McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307-14.
- Waters AH. Autoimmune thrombocytopenia: clinical aspects. Semin Hematol 1992;2:18-25.
- Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999;105:871-5.
- Zeller B, Helgestad J, Hellebostad M, et al. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol 200;17:551-8.
- Kelton JG. The serological investigation of patients with autoimmune thrombocytopenia. Thromb Haemost 1995;74:228-33.
- Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999;104:442-7.
- Provan D, Newland A, Norfolk D, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 203;120:574-96.
- Allen DL, Murphy MF. Evaluation of an enzyme- linked immunosorbent assay kit (GTI PakPlus) for the detection of antibodies against human platelet antigens. Transfus Med 1999;9:383-6.
- Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (P1A1, Zwa) as determined by antenatal screening. Blood 1998;92(7):2280-7.
- Murphy MF,Verjee S, Greaves M. Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia. Br J Haematol 1999;105:123-6.
- Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune neonatal thrombocytopenia. Lancet 1989;1:363-6.
- Kaplan C, Morel-Kopp MC, Kroll H, et al. HPA-5b (Bra) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991;78:425-9.
- Décary F, L’Abbé D, Tremblay L, Chartrand P. The immune response to the HPA-1a antigen: association with HLA-DRw52a. Transfus Med 1991;1:55.
- Kaplan C, Daffos F, Forestier F, Morel MC, Chesnel N, Tchernia G. Current trends in neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Kaplan-Gouet C, Schlegel N, Salmon Ch, Mcgregor J, eds. Platelet immunology: fundamental and clinical aspects. Paris: Colloque INSERM/John Libbey Eurotext, 1991;267-78.
- Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 201;41:45-55.
- Murphy MF, Hambley H, Nicolaides K, Waters AH. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn 1996;16:1152-5.
- Morel-Kopp MC, Daviet L, McGregor J, Kaplan C. Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Blood Coagul Fibrinolysis, 1996;7:144-6.
- Kroll H, Kiefel V, Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sang 1998;74(suppl 2):345-54.
- Bessos H, Mirza S, McGill A,Williamson LM, Hadfield R, Murphy WG. A whole blood assay for platelet HPA1 (PlA1) phenotyping applicable to large-scale screening. Br J Haematol 1996;92:221-5.
- Garner SF, Smethurst PA, Merieux Y, et al. A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti-HPA-1a. Br J Haematol 200;108:440-7.
- Ranasinghe E, Walton JD, Hurd CM, et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 201;113:40-2.
- Adner MM, Fisch GR, Starobin SG, Aster RH. Use of compatible platelet transfusions in treatment of congenital isoimmune thrombocytopenic purpura. New Engl J Med 1969;280:244-7.
- Mueller-Eckhardt C, Kiefel V, Grubert A. High dose IgG treatment for neonatal alloimmune thrombocytopenia. Blut 1989;59:145-6.
- Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. New Engl J Med 1997;337:22-6.
- Engelfriet CP, Reesink HW, Kroll H, et al. International forum: Prenatal management of alloimmune thrombocytopenia. Vox Sang 203;84: 142-9.
- Kroll H, Muntean W, Kiefel V, et al. Anti-Koa als ursache der neonatalen alloimmunthrombo- zytopenie. Beitr Infusionsther Transfusionsmed 1994;32:244-6.
- Kaplan C, Murphy MF, Kroll H, Waters AH. Fetomaternal alloimmune thrombocytopenia: antenatal therapy with IVIgG and steroids—more questions than answers. Br J Haematol 1998;100: 62-5.
- Murphy MF,Waters AH, Doughty A, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia—report of 15 affected pregnancies. Transfus Med 1994;4:281-92.
- Birchall J, Murphy MF, Kaplan C, Kroll H. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 203;122:275-88.
- Mackenzie F, Brennand J, Peterkin M, Cameron A. Management of fetal alloimmune thrombocyto- penia—a less invasive option? J Obstet Gynaecol 1999;19:119-21.
- Radder CM, Brand A, Kanhai HHH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 201;185:683-8.
- Murphy MF, Williamson LM, Urbaniak SJ. Antenatal screening for fetomaternal alloimmune thrombocytopenia: should we be doing it? Vox Sang 202;83(Suppl.1):409-16.
- van Loghem JJ, Dorfmeijer H, van der Hart M, Schreuder F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang 1959;4:161–9.
- Shulman NR, Aster RH, Leitner A, Hiller MC. Immunoreactions involving platelets. V. Posttransfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in ‘autoimmunity’. J Clin Invest 1961;40:1597–620.
- Serious Hazards of Transfusion. Annual report 201–202. Serious hazards of transfusion scheme, Manchester, UK, 203. (www.shotuk.org).
- Watkins NA, Smethurst PA, Allen D, Smith GA, Ouwehand WH. Platelet alpha II beta 3 recombinant autoantibodies from the B-cell repertoire of a post-transfusion purpura patient. Br J Haematol 202;116:677-85.
- Becker T, Panzer S, Maas D, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol 1985;61:149-55.
- Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med 1980;31:509-40.
- British Committee for Standards in Haematology (203). Guidelines for the use of platelet transfusions. Br J Haematol 203;122:10-23.
- Slichter SJ. Mechanisms and management of platelet refractoriness. In: Nance SJ, ed. Transfusion medicine in the 1990’s. Arlington, VA: American Association of Blood Banks, 1990:95-179.
- Bishop JF, McGrath K,Wolf MM,et al. Clinical factors inf luencing the efficacy of pooled platelet transfusions. Blood 1998;71:383-7.
- Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-5.
- Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunisation. Transfus Med Rev 200;14: 180-96.
- The Trial to Reduce Alloimmunisation to Platelets Study Group. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunisation and refractoriness to platelet transfusions. New Eng J Med 1997;337:1861-9.
- Murphy MF, Waters AH. Immunological aspects of platelet transfusions. Br J Haematol 1985;60: 409-14.
- Kurz M, Greinix H, Hocker P, et al. Specificities of anti-platelets antibodies in multitransfused patients with hemato-oncological disorders. Br J Haematol 1996;95:564-9.
- Godeau B, Fromont P, Seror T, Duedari N, Bierling P. Platelet alloimmunisation after multiple transfusion: A prospective study of 50 patients. Br J Haematol 1992;81:395-400.
- Meenaghan M, Judson PA, Yousaf K, Lewis L, Pamphilon DH. Antibodies to platelet glycoprotein V in polytransfused patients with hematological disease. Vox Sang 1993;64:167-70.
- Kekomaki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness: The use of platelet transfusions matched for both human leukocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunised patients with leukaemia. Eur J Haematol 1998;60:112-8.
- Christie D J, Van Buren N, Lennon SS, Putman JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood 1990;75:518-23.
- Warentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 203;121:535-55.
- Warkentin TE. Heparin-induced thrombocytopenia and thrombosis. Hematology 203. American Society of Hematology Education Program Book, 203;503-9.
- Campbell K, Garner SF, Hurd C, et al. Teicoplanin- dependent platelet antibodies as a cause of severe thrombocytopenia (abstract). J Thromb Haemost 203;1(suppl 1)OC024.
DOI: https://doi.org/10.21307/immunohematology-2019-430 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 89 - 102
Published on: May 15, 2020
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2020 A. Norton, D.L. Allen, M.F. Murphy, published by American National Red Cross
This work is licensed under the Creative Commons License.